Buy Or Sell Opportunity • Jun 02
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.3% to ₹636. The fair value is estimated to be ₹800, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 5.6%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 24% in the next 2 years. Reported Earnings • May 26
Full year 2026 earnings released: EPS: ₹19.27 (vs ₹30.06 in FY 2025) Full year 2026 results: EPS: ₹19.27 (down from ₹30.06 in FY 2025). Revenue: ₹18.3b (down 14% from FY 2025). Net income: ₹1.75b (down 36% from FY 2025). Profit margin: 9.6% (down from 13% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 11
Aarti Pharmalabs Limited to Report Q4, 2026 Results on May 18, 2026 Aarti Pharmalabs Limited announced that they will report Q4, 2026 results on May 18, 2026 Declared Dividend • Feb 11
Dividend of ₹1.50 announced Shareholders will receive a dividend of ₹1.50. Ex-date: 16th February 2026 Payment date: 11th March 2026 Dividend yield will be 0.5%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 12% per year over the past 2 years. However, payments have been volatile during that time. Earnings per share has grown by 23% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 10
Third quarter 2026 earnings released: EPS: ₹5.29 (vs ₹8.16 in 3Q 2025) Third quarter 2026 results: EPS: ₹5.29 (down from ₹8.16 in 3Q 2025). Revenue: ₹4.32b (down 20% from 3Q 2025). Net income: ₹479.6m (down 35% from 3Q 2025). Profit margin: 11% (down from 14% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 29
Aarti Pharmalabs Limited to Report Q3, 2026 Results on Feb 09, 2026 Aarti Pharmalabs Limited announced that they will report Q3, 2026 results on Feb 09, 2026 Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹713, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 9.3% over the past year. Reported Earnings • Nov 10
Second quarter 2026 earnings released: EPS: ₹3.08 (vs ₹6.03 in 2Q 2025) Second quarter 2026 results: EPS: ₹3.08 (down from ₹6.03 in 2Q 2025). Revenue: ₹4.18b (down 8.7% from 2Q 2025). Net income: ₹279.2m (down 49% from 2Q 2025). Profit margin: 6.7% (down from 12% in 2Q 2025). The decrease in margin was driven by lower revenue. Announcement • Oct 27
Aarti Pharmalabs Limited to Report Q2, 2026 Results on Nov 09, 2025 Aarti Pharmalabs Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 09, 2025 Upcoming Dividend • Sep 08
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 15 September 2025. Payment date: 20 October 2025. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%). Announcement • Aug 19
Aarti Pharmalabs Limited, Annual General Meeting, Sep 22, 2025 Aarti Pharmalabs Limited, Annual General Meeting, Sep 22, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹5.46 (vs ₹6.12 in 1Q 2025) First quarter 2026 results: EPS: ₹5.46 (down from ₹6.12 in 1Q 2025). Revenue: ₹3.88b (down 30% from 1Q 2025). Net income: ₹495.0m (down 11% from 1Q 2025). Profit margin: 13% (up from 10.0% in 1Q 2025). The increase in margin was driven by lower expenses. Announcement • Aug 02
Aarti Pharmalabs Limited to Report Q1, 2026 Results on Aug 12, 2025 Aarti Pharmalabs Limited announced that they will report Q1, 2026 results on Aug 12, 2025 New Risk • Jun 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • May 14
Full year 2025 earnings released: EPS: ₹30.06 (vs ₹23.93 in FY 2024) Full year 2025 results: EPS: ₹30.06 (up from ₹23.93 in FY 2024). Revenue: ₹21.3b (up 15% from FY 2024). Net income: ₹2.72b (up 26% from FY 2024). Profit margin: 13% (up from 12% in FY 2024). The increase in margin was driven by higher revenue. Announcement • May 10
Aarti Pharmalabs Limited Recommends Dividend for the Financial Year Ended March 31, 2025 Aarti Pharmalabs Limited at its board meeting held on May 10, 2025, recommended dividend of INR 2.50 (50%) per Equity Share of Face Value of INR 5 each for the Financial Year ended March 31, 2025, subject to the approval of the Shareholders at the upcoming Annual General Meeting of the Company. New Risk • May 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Announcement • Apr 25
Aarti Pharmalabs Limited to Report Q4, 2025 Results on May 10, 2025 Aarti Pharmalabs Limited announced that they will report Q4, 2025 results at 4:00 PM, Indian Standard Time on May 10, 2025 Announcement • Feb 06
Aarti Pharmalabs Limited Approves Interim Dividend for the Financial Year 2024-25 Aarti Pharmalabs Limited informed that the Board of Directors of the Company at their meeting held on February 05, 2025 have declared Interim Dividend of INR 2.5/- (@50%) per Equity Share of INR 5/- each for the Financial Year 2024-25. Please note that as per the Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, February 14, 2025 has been fixed as `Record Date' for the purpose of payment of Interim Dividend. Announcement • Jan 28
Aarti Pharmalabs Limited to Report Q3, 2025 Results on Feb 05, 2025 Aarti Pharmalabs Limited announced that they will report Q3, 2025 results on Feb 05, 2025 Announcement • Jan 18
Aarti Pharmalabs Limited Announces Re-Opening of Manufacturing Activities At the Company's Vapi Plant In continuation of the intimation dated January 03, 2025 relating to Closure of Manufacturing activities at the Company's Vapi Plant, pursuant to the provisions of the SEBI (Listing Obligations and Disclosures Requirements) 2015, Aarti Pharmalabs Limited informed the Exchanges that Gujarat Pollution Control Board (`GPCB') vide its letter dated January 17, 2025 has revoked the closure directions dated January 02, 2025 for a period of three months from the date of issue of order as per the procedure. Further, the Company has paid an Interim Environmental Damage Compensation of INR 340,000 to GPCB. The Company is in the process of resuming operations at its plant located at Plot No. 22/C-1 Phase1, GIDC Vapi- 396195 Tal; Pardi, Dist. Valsad, Gujarat, India. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹676, the stock trades at a trailing P/E ratio of 26.9x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 35% over the past year. Announcement • Dec 13
Aarti Pharmalabs Limited Appoints Jeevan Mondkar as Company Secretary and Compliance Officer Aarti Pharmalabs Limited informedu that the Board of Directors has, at its meeting held on December 13, 2024, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Shri Jeevan Mondkar (ACS: A22565) as the Company Secretary, Compliance Officer and Key Managerial Personnel of the Company effective December 13, 2024. Mr. Jeevan Mondkar (ACS: A22565), is a member of the Institute of Company Secretaries of India and holds a law degree from Mumbai University. Mr. Jeevan has over 19 years of rich experience in the areas of corporate laws, corporate governance, and legal advisory role of Listed Companies. His core skills comprise of Company Secretarial Affairs, Corporate Law, Due Diligence, Mergers & Acquisitions, Litigation Management, Contract drafting and negotiation, Ethics and Stakeholders Engagement. In the past, he has worked with Welspun, Merck, P&G and Wockhardt. In his last assignment, he served Apcotex Industries Limited as Company Secretary and Legal Head. Reported Earnings • Oct 29
Second quarter 2025 earnings released: EPS: ₹6.03 (vs ₹5.72 in 2Q 2024) Second quarter 2025 results: EPS: ₹6.03 (up from ₹5.72 in 2Q 2024). Revenue: ₹4.63b (up 5.2% from 2Q 2024). Net income: ₹546.2m (up 5.4% from 2Q 2024). Profit margin: 12% (in line with 2Q 2024). Announcement • Oct 21
Aarti Pharmalabs Limited to Report Q2, 2025 Results on Oct 28, 2024 Aarti Pharmalabs Limited announced that they will report Q2, 2025 results on Oct 28, 2024 Announcement • Jul 29
Aarti Pharmalabs Limited to Report Q1, 2025 Results on Aug 05, 2024 Aarti Pharmalabs Limited announced that they will report Q1, 2025 results on Aug 05, 2024 Announcement • Jul 13
Aarti Pharmalabs Limited, Annual General Meeting, Aug 07, 2024 Aarti Pharmalabs Limited, Annual General Meeting, Aug 07, 2024, at 11:00 Indian Standard Time. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹617, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 81% over the past year. Reported Earnings • May 14
Full year 2024 earnings released: EPS: ₹23.93 (vs ₹21.35 in FY 2023) Full year 2024 results: EPS: ₹23.93 (up from ₹21.35 in FY 2023). Revenue: ₹18.6b (down 4.5% from FY 2023). Net income: ₹2.17b (up 12% from FY 2023). Profit margin: 12% (up from 9.9% in FY 2023). The increase in margin was driven by lower expenses. Announcement • May 05
Aarti Pharmalabs Limited to Report Q4, 2024 Results on May 13, 2024 Aarti Pharmalabs Limited announced that they will report Q4, 2024 results on May 13, 2024 Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: ₹5.82 (vs ₹5.26 in 3Q 2023) Third quarter 2024 results: EPS: ₹5.82 (up from ₹5.26 in 3Q 2023). Revenue: ₹4.49b (down 4.9% from 3Q 2023). Net income: ₹527.6m (up 11% from 3Q 2023). Profit margin: 12% (up from 10% in 3Q 2023). The increase in margin was driven by lower expenses. Announcement • Feb 07
Aarti Pharmalabs Limited Declares Interim Dividend for the Financial Year 2023-24 The Board of Directors of Aarti Pharmalabs Limited have declared Interim Dividend of INR 2/- (@40%) per Equity Share of INR 5/- each for the Financial Year 2023-24, at the board meeting was held on February 7, 2024. Please note that as per the Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, February 19, 2024 has been fixed as `Record Date' for the purpose of payment of Interim Dividend. Announcement • Jan 31
Aarti Pharmalabs Limited to Report Q3, 2024 Results on Feb 07, 2024 Aarti Pharmalabs Limited announced that they will report Q3, 2024 results on Feb 07, 2024 Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹471, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹5.72 (vs ₹5.64 in 2Q 2023) Second quarter 2024 results: EPS: ₹5.72 (up from ₹5.64 in 2Q 2023). Revenue: ₹4.40b (down 17% from 2Q 2023). Net income: ₹518.0m (up 1.4% from 2Q 2023). Profit margin: 12% (up from 9.6% in 2Q 2023). The increase in margin was driven by lower expenses. Buying Opportunity • Nov 08
Now 21% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be ₹497, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last year. Meanwhile, the company has become profitable. Announcement • Oct 31
Aarti Pharmalabs Limited to Report Q2, 2024 Results on Nov 07, 2023 Aarti Pharmalabs Limited announced that they will report Q2, 2024 results on Nov 07, 2023 Buying Opportunity • Oct 20
Now 20% undervalued Over the last 90 days, the stock is up 18%. The fair value is estimated to be ₹499, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last year. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹450, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Buying Opportunity • Aug 31
Now 21% undervalued Over the last 90 days, the stock is up 8.1%. The fair value is estimated to be ₹498, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last year. Meanwhile, the company has become profitable. Announcement • Aug 24
Aarti Pharmalabs Limited, Annual General Meeting, Sep 14, 2023 Aarti Pharmalabs Limited, Annual General Meeting, Sep 14, 2023, at 11:00 Indian Standard Time. Agenda: To consider and approve the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2023 together with the Reports of the Board of Directors and Auditors' thereon; to consider and approve the appointment of a Director in place of Shri Rajendra V. Gogri who retires by rotation and being eligible, offers his candidature for re-appointment; and to consider other matters. Buying Opportunity • Aug 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be ₹426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last year. Meanwhile, the company has become profitable. Reported Earnings • Aug 06
First quarter 2024 earnings released: EPS: ₹5.20 (vs ₹5.72 in 1Q 2023) First quarter 2024 results: EPS: ₹5.20 (down from ₹5.72 in 1Q 2023). Revenue: ₹4.58b (flat on 1Q 2023). Net income: ₹470.9m (down 9.2% from 1Q 2023). Profit margin: 10% (down from 11% in 1Q 2023). Announcement • Jul 29
Aarti Pharmalabs Limited to Report Q1, 2024 Results on Aug 05, 2023 Aarti Pharmalabs Limited announced that they will report Q1, 2024 results on Aug 05, 2023 Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹366, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Recent Insider Transactions • Feb 15
Insider recently bought ₹4.9m worth of stock On the 9th of February, Manjula Sangoi bought around 15k shares on-market at roughly ₹323 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. 
